AtriCure, Inc. Hits 52-Week Low at USD 25.37 Amid Market Struggles

AtriCure, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 25.37 on June 2, 2026. This marks a significant decline from its 52-week high of USD 43.18, highlighting the stock's volatility over the past year. Despite the challenges reflected in its stock price, AtriCure has shown a one-year performance of 18.35%, which is notably lower than the S&P 500's performance of 28.2%. The company's market capitalization stands at USD 1,516 million, indicating its position within the small-cap segment of the market. Financial metrics reveal that AtriCure is currently loss-making, with a negative return on equity of -1.16% and a debt-to-equity ratio of -0.21. The company does not offer a dividend yield, and its price-to-book ratio is 3.08. These figures provide insight into AtriCure's financial health and market standing as it navigates through this challenging period.